Saturday, July 5, 2025 7/5/2025

Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).

Award Number: R44CA265510
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2021
PERIOD OF PERFORMANCE END DATE: 06/30/2026

Group Awards By:

View Award Description

Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL). - PROJECT SUMMARY Cancer has killed over 600,000 people in US in 2020. The cost for healthcare and society is unbearable: because of cancer, $180B healthcare expenditure and $134B lost productivity are recorded every year. This is happening despite recent advancements in therapy and the emergence of an ever expanding array of new therapeutics for the over 1.8M new cancer patients every year. Indeed, because of the multitude and redundancy of mechanisms contributing to cancer growth, therapies are often ineffective. Several components should be targeted at the same time in order to maximize therapy outcome. However, this is particular hard to attain because of 1) the striking variability among cancers and the limited number of cancer specific targets 2) the ability of cancer cells to orchestrate a microenvironment of healthy tissue and cells around them, that promote cancer growth and therapy resistance. Boston Immune Technologies and Therapeutics (BITT) is developing BITT-1492, able to target both cancer cells and their microenvironment. BITT-1492 is an antagonist antibody against TNFR2 – a receptor highly expressed in cancer tissue and immune suppressive cells in the microenvironment, where it mediates pro-survival signaling. Thanks to BITT’s proprietary antibody design platform, BITT-1492 is the first and only antibody able to dominantly shut down TNFR2 signaling. Due to selective expression and key role of TNFR2 for a variety of cancers and tumor microenvironment cells, BITT-1492 will find application in the therapy of several cancers, starting with Cutaneous T cell Lymphoma (CTCL), where TNFR2 is known to act as an extremely potent oncogene. BITT has already completed extensive pre-clinical validation for BITT-1492, demonstrating potent activity in CTCL, colon and ovarian cancers. In the proposed Fast-Track project, BITT will complete a pre-clinical toxicology and pharmacology assessment of BITT-1492 to obtain relevant data for an Investigational New Drug (IND) application. This will be accomplished by performing, in line with ICH guidelines, an exploratory small-scale toxicology study to be carried out in Phase I, that will demonstrate the safety of use of BITT-1492 for a wider IND-enabling toxicology and pharmacokinetic studies in Phase II. As part of the PhaseII BITT will also test the suitability of BITT-1492 production process for cGMP standard compliance. At the end of the SBIR project, BITT will be ready to advance BITT-1492 to clinical testing for which a combination of Venture Capital seed funds and SBIR PhaseIIb are expected to be leveraged. The successful completion of this project and initial clinical testing evidence will help to secure the already expressed interest of pharmaceutical companies with whom BITT will engage to complete late-stage clinical testing and launch BITT-1492 into international markets.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $2,342,454 )
2024	2024	BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC.	81 WALNUT ST	WINCHESTER	MA	01890	MIDDLESEX	USA	Cancer Treatment Research	000	3	11/22/2023	NON-COMPETING CONTINUATION	$776,973
2024	2024	BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC.	81 WALNUT ST	WINCHESTER	MA	01890	MIDDLESEX	USA	Cancer Treatment Research	004	4	7/3/2024	COMPETING CONTINUATION	$1,565,481
2024	2024	BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC.	81 WALNUT ST	WINCHESTER	MA	01890	MIDDLESEX	USA	Cancer Treatment Research	003	3	6/11/2024	NON-COMPETING CONTINUATION	$0
2024	2024	BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC.	81 WALNUT ST	WINCHESTER	MA	01890	MIDDLESEX	USA	Cancer Treatment Research	001	3	2/5/2024	NON-COMPETING CONTINUATION	$0
2024	2021	BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC.	81 WALNUT ST	WINCHESTER	MA	01890	MIDDLESEX	USA	Cancer Treatment Research	002	1	6/11/2024	NEW	$0
														Subtotal = $2,342,454

Issue Date FY: 2023 ( Subtotal = $1,221,684 )
2023	2023	BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC.	81 WALNUT ST	WINCHESTER	MA	01890	MIDDLESEX	USA	Cancer Treatment Research	001	2	4/25/2023	EXTENSION WITH OR WITHOUT FUNDS	$1,221,684
2023	2021	BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC.	81 WALNUT ST	WINCHESTER	MA	01890	MIDDLESEX	USA	Cancer Treatment Research	000	1	4/25/2023	NEW	$0
														Subtotal = $1,221,684

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2021	BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC.	81 WALNUT ST	WINCHESTER	MA	01890	MIDDLESEX	USA	Cancer Treatment Research	000	1	7/6/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $397,959 )
2021	2021	BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC.	81 WALNUT ST	WINCHESTER	MA	01890	MIDDLESEX	USA	Cancer Treatment Research	001	1	9/2/2021	NEW	$0
2021	2021	BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC.	81 WALNUT ST	WINCHESTER	MA	01890	MIDDLESEX	USA	Cancer Treatment Research	000	1	8/31/2021	NEW	$397,959
														Subtotal = $397,959

Grand Total All Awards = $3,962,097

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).

Award Number: R44CA265510

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2021

PERIOD OF PERFORMANCE END DATE: 06/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer